{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:32:08Z","timestamp":1791235928064,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:00:00Z","timestamp":1718409600000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100002081","name":"Irish Research Council","doi-asserted-by":"publisher","award":["GOIPG\/2021\/1213"],"award-info":[{"award-number":["GOIPG\/2021\/1213"]}],"id":[{"id":"10.13039\/501100002081","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010414","name":"Health Research Board","doi-asserted-by":"publisher","award":["RL-15-1579"],"award-info":[{"award-number":["RL-15-1579"]}],"id":[{"id":"10.13039\/100010414","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010414","name":"Health Research Board","doi-asserted-by":"publisher","award":["SDAP-2021-020"],"award-info":[{"award-number":["SDAP-2021-020"]}],"id":[{"id":"10.13039\/100010414","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012921","name":"Royal College of Surgeons in Ireland","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012921","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s40261-024-01369-9","type":"journal-article","created":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T07:03:05Z","timestamp":1718434985000},"page":"439-453","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Drug\u2013Drug Interactions and Their Association with Adverse Health Outcomes in the Older Community-Dwelling Population: A Prospective Cohort Study"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3944-8326","authenticated-orcid":false,"given":"John E.","family":"Hughes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2861-7665","authenticated-orcid":false,"given":"Kathleen E.","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7137-5737","authenticated-orcid":false,"given":"Caitriona","family":"Cahir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,15]]},"reference":[{"issue":"9","key":"1369_CR1","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1111\/jgs.15419","volume":"66","author":"N Parekh","year":"2018","unstructured":"Parekh N, Ali K, Page A, Roper T, Rajkumar C. Incidence of medication-related harm in older adults after hospital discharge: a systematic review. J Am Geriatr Soc. 2018;66(9):1812\u201322.","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"1369_CR2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1517\/14740338.2012.631910","volume":"11","author":"L Magro","year":"2012","unstructured":"Magro L, Moretti U, Leone R. Epidemiology and characteristics of adverse drug reactions caused by drug\u2013drug interactions. Expert Opin Drug Saf. 2012;11(1):83\u201394.","journal-title":"Expert Opin Drug Saf"},{"key":"1369_CR3","volume-title":"Stockley's drug interactions: a source book of interactions, their mechanisms, clinical importance and management","author":"CL Preston","year":"2019","unstructured":"Preston CL. Stockley\u2019s drug interactions: a source book of interactions, their mechanisms, clinical importance and management. 12th ed. London: Pharmaceutical Press; 2019.","edition":"12"},{"issue":"6","key":"1369_CR4","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/pds.1351","volume":"16","author":"ML Becker","year":"2007","unstructured":"Becker ML, Kallewaard M, Caspers PW, Visser LE, Leufkens HG, Stricker BH. Hospitalisations and emergency department visits due to drug\u2013drug interactions: a literature review. Pharmacoepidemiol Drug Saf. 2007;16(6):641\u201351.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"13","key":"1369_CR5","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1001\/jama.289.13.1652","volume":"289","author":"DN Juurlink","year":"2003","unstructured":"Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA. 2003;289(13):1652\u20138.","journal-title":"JAMA"},{"key":"1369_CR6","doi-asserted-by":"crossref","unstructured":"Hughes JE, Waldron C, Bennett KE, Cahir C. Prevalence of drug\u2013drug interactions in older community-dwelling individuals: a systematic review and meta-analysis. Drugs & Aging. 2023 2023\/02\/01;40(2):117-34.","DOI":"10.1007\/s40266-022-01001-5"},{"issue":"1","key":"1369_CR7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2165\/00002018-199309010-00005","volume":"9","author":"CA Jankel","year":"1993","unstructured":"Jankel CA, Fitterman LK. Epidemiology of drug-drug interactions as a cause of hospital admissions. Drug Saf. 1993;9(1):51\u20139.","journal-title":"Drug Saf"},{"key":"1369_CR8","doi-asserted-by":"crossref","unstructured":"Hughes JE, Moriarty F, Bennett KE, Cahir C. Drug\u2010drug interactions and the risk of adverse drug reaction\u2010related hospital admissions in the older population. British journal of clinical pharmacology. 2023 2023\/20\/11.","DOI":"10.1093\/ageing\/afad156.293"},{"issue":"7\u20138","key":"1369_CR9","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1345\/aph.1P627","volume":"45","author":"SV Tach\u00e9","year":"2011","unstructured":"Tach\u00e9 SV, S\u00f6nnichsen A, Ashcroft DM. Prevalence of adverse drug events in ambulatory care: a systematic review. Ann Pharmacother. 2011;45(7\u20138):977\u201389.","journal-title":"Ann Pharmacother"},{"issue":"10","key":"1369_CR10","doi-asserted-by":"publisher","first-page":"795","DOI":"10.7326\/0003-4819-140-10-200405180-00009","volume":"140","author":"JR Nebeker","year":"2004","unstructured":"Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician\u2019s guide to terminology, documentation, and reporting. Ann Intern Med. 2004;140(10):795\u2013801.","journal-title":"Ann Intern Med"},{"issue":"1","key":"1369_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/2042098615615472","volume":"7","author":"AH Lavan","year":"2016","unstructured":"Lavan AH, Gallagher P. Predicting risk of adverse drug reactions in older adults. Therap Adv Drug Saf. 2016;7(1):11\u201322.","journal-title":"Therap Adv Drug Saf"},{"issue":"9","key":"1369_CR12","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1001\/jama.289.9.1107","volume":"289","author":"JH Gurwitz","year":"2003","unstructured":"Gurwitz JH, Field TS, Harrold LR, Rothschild J, Debellis K, Seger AC, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003;289(9):1107\u201316.","journal-title":"JAMA"},{"issue":"1","key":"1369_CR13","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/bcp.12161","volume":"77","author":"C Cahir","year":"2014","unstructured":"Cahir C, Bennett K, Teljeur C, Fahey T. Potentially inappropriate prescribing and adverse health outcomes in community dwelling older patients. Br J Clin Pharmacol. 2014;77(1):201\u201310.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1369_CR14","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/gerona\/glw140","volume":"72","author":"E Wallace","year":"2017","unstructured":"Wallace E, McDowell R, Bennett K, Fahey T, Smith SM. Impact of potentially inappropriate prescribing on adverse drug events, health related quality of life and emergency hospital attendance in older people attending general practice: a prospective cohort study. J Gerontol Ser A Biomed Sci Med Sci. 2017;72(2):271\u20137.","journal-title":"J Gerontol Ser A Biomed Sci Med Sci"},{"key":"1369_CR15","doi-asserted-by":"crossref","unstructured":"P\u00e9rez T, Moriarty F, Wallace E, McDowell R, Redmond P, Fahey T. Prevalence of potentially inappropriate prescribing in older people in primary care and its association with hospital admission: longitudinal study. BMJ. 2018;363.","DOI":"10.1136\/bmj.k4524"},{"issue":"2","key":"1369_CR16","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1111\/bcp.15530","volume":"89","author":"N Parodi L\u00f3pez","year":"2023","unstructured":"Parodi L\u00f3pez N, Belfrage B, Koldestam A, L\u00f6nnbro J, Svensson SA, Wallerstedt SM. Revisiting the inter-rater reliability of drug treatment assessments according to the STOPP\/START criteria. Br J Clin Pharmacol. 2023;89(2):832\u201342.","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"1369_CR17","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1007\/s00228-022-03337-8","volume":"78","author":"N Parodi L\u00f3pez","year":"2022","unstructured":"Parodi L\u00f3pez N, Svensson SA, Wallerstedt SM. Clinical relevance of potentially inappropriate medications and potential prescribing omissions according to explicit criteria\u2014a validation study. Eur J Clin Pharmacol. 2022;78(8):1331\u20139.","journal-title":"Eur J Clin Pharmacol"},{"key":"1369_CR18","doi-asserted-by":"crossref","unstructured":"Klopotowska JE, Leopold JH, Bakker T, Yasrebi\u2010de Kom I, Engelaer FM, de Jonge E, et al. Adverse drug events caused by three high\u2010risk drug\u2010drug interactions in patients admitted to intensive care units: a multicentre retrospective observational study. British journal of clinical pharmacology. 2023.","DOI":"10.1111\/bcp.15882"},{"issue":"19","key":"1369_CR19","doi-asserted-by":"publisher","first-page":"19711","DOI":"10.18632\/aging.104018","volume":"12","author":"F Swart","year":"2020","unstructured":"Swart F, Bianchi G, Lenzi J, Iommi M, Maestri L, Raschi E, et al. Risk of hospitalization from drug-drug interactions in the elderly: real-world evidence in a large administrative database. Aging (Albany NY). 2020;12(19):19711.","journal-title":"Aging (Albany NY)."},{"issue":"6","key":"1369_CR20","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1111\/cts.13262","volume":"15","author":"L Letinier","year":"2022","unstructured":"Letinier L, Pujade I, Duthoit P, Evrard G, Salvo F, Gil-Jardine C, et al. Emergency department admissions induced by drug\u2013drug interactions in the elderly: a cross-sectional study. Clin Transl Sci. 2022;15(6):1472\u201381.","journal-title":"Clin Transl Sci"},{"issue":"1","key":"1369_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12877-021-02532-z","volume":"21","author":"L Zerah","year":"2021","unstructured":"Zerah L, Henrard S, Wilting I, O\u2019Mahony D, Rodondi N, Dalleur O, et al. Prevalence of drug-drug interactions in older people before and after hospital admission: analysis from the OPERAM trial. BMC Geriatr. 2021;21(1):1\u201311.","journal-title":"BMC Geriatr"},{"key":"1369_CR22","doi-asserted-by":"crossref","unstructured":"O\u010dovsk\u00e1 Z, Ma\u0159\u00edkov\u00e1 M, Vl\u010dek J. Potentially clinically significant drug-drug interactions in older patients admitted to the hospital: a cross-sectional study. Front Pharmacol. 2023;14.","DOI":"10.3389\/fphar.2023.1088900"},{"issue":"8","key":"1369_CR23","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","volume":"147","author":"E Von Elm","year":"2007","unstructured":"Von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147(8):573\u20137.","journal-title":"Ann Intern Med"},{"key":"1369_CR24","doi-asserted-by":"crossref","unstructured":"Langan SM, Schmidt SA, Wing K, Ehrenstein V, Nicholls SG, Filion KB, et al. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). Bmj. 2018;363.","DOI":"10.1136\/bmj.k3532"},{"issue":"11","key":"1369_CR25","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1007\/s00228-017-2310-7","volume":"73","author":"S-J Sinnott","year":"2017","unstructured":"Sinnott S-J, Bennett K, Cahir C. Pharmacoepidemiology resources in Ireland\u2014an introduction to pharmacy claims data. Eur J Clin Pharmacol. 2017;73(11):1449\u201355.","journal-title":"Eur J Clin Pharmacol"},{"key":"1369_CR26","unstructured":"Central Statistics Office. Women and Men in Ireland 2013: persons with a medical card. [cited Date Accessed: 10 September, 2023]; Available from: https:\/\/www.cso.ie\/en\/releasesandpublications\/ep\/p-wamii\/womenandmeninireland2013\/healthlist\/health\/#d.en.65619"},{"key":"1369_CR27","doi-asserted-by":"crossref","unstructured":"Tobi H, Faber A, Van Den Berg PB, Drane JW, de Jong\u2010van den Berg LT. Studying co\u2010medication patterns: the impact of definitions. Pharmacoepidemiol Drug Saf. 2007;16(4):405-11.","DOI":"10.1002\/pds.1304"},{"key":"1369_CR28","unstructured":"Hughes JE. Drug-drug interaction list for pharmacoepidemiology research. 2023 [cited; Available from: https:\/\/osf.io\/y3gmx\/"},{"issue":"2","key":"1369_CR29","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1370\/afm.2359","volume":"17","author":"C Cahir","year":"2019","unstructured":"Cahir C, Wallace E, Cummins A, Teljeur C, Byrne C, Bennett K, et al. Identifying adverse drug events in older community-dwelling patients. Ann Fam Med. 2019;17(2):133\u201340.","journal-title":"Ann Fam Med."},{"key":"1369_CR30","doi-asserted-by":"crossref","unstructured":"Devlin N, Parkin D, Janssen B, Devlin N, Parkin D, Janssen B. An introduction to EQ-5D instruments and their applications. Methods Anal Report EQ-5D Data. 2020:1\u201322.","DOI":"10.1007\/978-3-030-47622-9_1"},{"key":"1369_CR31","doi-asserted-by":"crossref","unstructured":"Rabin R, Charro Fd. EQ-SD: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337\u201343.","DOI":"10.3109\/07853890109002087"},{"issue":"11","key":"1369_CR32","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","volume":"35","author":"P Dolan","year":"1997","unstructured":"Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095\u2013108.","journal-title":"Med Care"},{"issue":"11","key":"1369_CR33","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1007\/s11136-022-03158-3","volume":"31","author":"I Buchholz","year":"2022","unstructured":"Buchholz I, Marten O, Janssen MF. Feasibility and validity of the EQ-5D-3L in the elderly Europeans: a secondary data analysis using SHARE (d) data. Qual Life Res. 2022;31(11):3267\u201382.","journal-title":"Qual Life Res"},{"issue":"8","key":"1369_CR34","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1111\/j.1532-5415.2004.52367.x","volume":"52","author":"TS Field","year":"2004","unstructured":"Field TS, Gurwitz JH, Harrold LR, Rothschild J, DeBellis KR, Seger AC, et al. Risk factors for adverse drug events among older adults in the ambulatory setting. J Am Geriatr Soc. 2004;52(8):1349\u201354.","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"1369_CR35","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12955-022-02080-z","volume":"20","author":"F Siqeca","year":"2022","unstructured":"Siqeca F, Yip O, Mendieta MJ, Schwenkglenks M, Zeller A, De Geest S, et al. Factors associated with health-related quality of life among home-dwelling older adults aged 75 or older in Switzerland: a cross-sectional study. Health Qual Life Outcomes. 2022;20(1):166.","journal-title":"Health Qual Life Outcomes"},{"issue":"8","key":"1369_CR36","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1097\/MLR.0000000000000171","volume":"52","author":"E Wallace","year":"2014","unstructured":"Wallace E, Stuart E, Vaughan N, Bennett K, Fahey T, Smith SM. Risk prediction models to predict emergency hospital admission in community-dwelling adults: a systematic review. Med Care. 2014;52(8):751.","journal-title":"Med Care"},{"issue":"6","key":"1369_CR37","doi-asserted-by":"publisher","first-page":"558","DOI":"10.4097\/kja.19087","volume":"72","author":"JH Kim","year":"2019","unstructured":"Kim JH. Multicollinearity and misleading statistical results. Korean J Anesthesiol. 2019;72(6):558.","journal-title":"Korean J Anesthesiol"},{"issue":"9","key":"1369_CR38","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1002\/pds.5083","volume":"29","author":"S Suissa","year":"2020","unstructured":"Suissa S, Dell\u2019Aniello S. Time-related biases in pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2020;29(9):1101\u201310.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"1369_CR39","first-page":"27457","volume":"16","author":"EY Liu","year":"2014","unstructured":"Liu EY, Vasudev A. Mania induced by clarithromycin in a geriatric patient taking low-dose prednisone. Prim Care Compan CNS Disord. 2014;16(3):27457.","journal-title":"Prim Care Compan CNS Disord"},{"issue":"3","key":"1369_CR40","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.amjmed.2004.09.018","volume":"118","author":"JH Gurwitz","year":"2005","unstructured":"Gurwitz JH, Field TS, Judge J, Rochon P, Harrold LR, Cadoret C, et al. The incidence of adverse drug events in two large academic long-term care facilities. Am J Med. 2005;118(3):251\u20138.","journal-title":"Am J Med"},{"issue":"5","key":"1369_CR41","first-page":"71","volume":"113","author":"A Smith","year":"2020","unstructured":"Smith A, Barry M. Oral anticoagulants-utilisation and expenditure under the community drugs schemes. Ir Med J. 2020;113(5):71.","journal-title":"Ir Med J"},{"issue":"7","key":"1369_CR42","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","volume":"43","author":"A Vahanian","year":"2022","unstructured":"Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC\/EACTS Guidelines for the management of valvular heart disease: developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2022;43(7):561\u2013632.","journal-title":"Eur Heart J"},{"issue":"09","key":"1369_CR43","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1160\/TH05-03-0166","volume":"94","author":"C Gasse","year":"2005","unstructured":"Gasse C, Hollowell J, Meier CR, Haefeli WE. Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin. Thromb Haemost. 2005;94(09):537\u201343.","journal-title":"Thromb Haemost"},{"issue":"5","key":"1369_CR44","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/clpt.2008.150","volume":"84","author":"H Schelleman","year":"2008","unstructured":"Schelleman H, Bilker WB, Brensinger CM, Han X, Kimmel SE, Hennessy S. Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleeding. Clin Pharmacol Ther. 2008;84(5):581\u20138.","journal-title":"Clin Pharmacol Ther"},{"key":"1369_CR45","doi-asserted-by":"crossref","unstructured":"AL\u2010Musawe L, Torre C, Guerreiro JP, Rodrigues AT, Raposo JF, Mota\u2010Filipe H, et al. Polypharmacy, potentially serious clinically relevant drug\u2010drug interactions, and inappropriate medicines in elderly people with type 2 diabetes and their impact on quality of life. Pharm Res Perspect. 8(4):e00621.","DOI":"10.1002\/prp2.621"},{"issue":"7","key":"1369_CR46","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1093\/gerona\/60.7.894","volume":"60","author":"S Perera","year":"2005","unstructured":"Perera S, Studenski S, Chandler JM, Guralnik JM. Magnitude and patterns of decline in health and function in 1 year affect subsequent 5-year survival. J Gerontol A Biol Sci Med Sci. 2005;60(7):894\u2013900.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"4","key":"1369_CR47","doi-asserted-by":"publisher","first-page":"257","DOI":"10.4103\/2279-042X.192461","volume":"5","author":"R Kheshti","year":"2016","unstructured":"Kheshti R, Aalipour M, Namazi S. A comparison of five common drug\u2013drug interaction software programs regarding accuracy and comprehensiveness. J Res Pharm Pract. 2016;5(4):257.","journal-title":"J Res Pharm Pract"},{"issue":"1","key":"1369_CR48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12911-022-01783-z","volume":"22","author":"G Van De Sijpe","year":"2022","unstructured":"Van De Sijpe G, Quintens C, Walgraeve K, Van Laer E, Penny J, De Vlieger G, et al. Overall performance of a drug\u2013drug interaction clinical decision support system: quantitative evaluation and end-user survey. BMC Med Inform Decis Mak. 2022;22(1):1\u201311.","journal-title":"BMC Med Inform Decis Mak"},{"issue":"12","key":"1369_CR49","first-page":"564","volume":"36","author":"S Battar","year":"2019","unstructured":"Battar S, Dickerson KRW, Sedgwick C, Cmelik T. Understanding principles of high reliability organizations through the eyes of VIONE: a clinical program to improve patient safety by deprescribing potentially inappropriate medications and reducing polypharmacy. Fed Pract. 2019;36(12):564.","journal-title":"Fed Pract"},{"key":"1369_CR50","doi-asserted-by":"crossref","unstructured":"Omuya H, Nickel C, Wilson P, Chewning B. A systematic review of randomised-controlled trials on deprescribing outcomes in older adults with polypharmacy. Int J Pharm Pract. 2023:riad025.","DOI":"10.1093\/ijpp\/riad025"},{"key":"1369_CR51","unstructured":"The World Health Organization. WHO Global Patient Safety Challenge: Medication Without Harm. 2017 [Cited Date Accessed: 12 May, 2021]; Available from: http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/255263\/WHO-HIS-SDS-2017.6-eng.pdf?ua=1&ua=1?sequence=1"},{"issue":"9823","key":"1369_CR52","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/S0140-6736(11)61817-5","volume":"379","author":"AJ Avery","year":"2012","unstructured":"Avery AJ, Rodgers S, Cantrill JA, Armstrong S, Cresswell K, Eden M, et al. A pharmacist-led information technology intervention for medication errors (PINCER): a multicentre, cluster randomised, controlled trial and cost-effectiveness analysis. Lancet. 2012;379(9823):1310\u20139.","journal-title":"Lancet"},{"issue":"4","key":"1369_CR53","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.sapharm.2013.08.006","volume":"10","author":"EC Tan","year":"2014","unstructured":"Tan EC, Stewart K, Elliott RA, George J. Pharmacist services provided in general practice clinics: a systematic review and meta-analysis. Res Social Adm Pharm. 2014;10(4):608\u201322.","journal-title":"Res Social Adm Pharm"},{"issue":"53","key":"1369_CR54","doi-asserted-by":"publisher","first-page":"53","DOI":"10.12688\/hrbopenres.13580.2","volume":"5","author":"C Waldron","year":"2023","unstructured":"Waldron C, Hughes J, Wallace E, Cahir C, Bennett K. Contexts and mechanisms relevant to General Practitioner (GP) based interventions to reduce adverse drug events (ADE) in community dwelling older adults: a rapid realist review. HRB Open Res. 2023;5(53):53.","journal-title":"HRB Open Res."},{"issue":"3","key":"1369_CR55","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/j.1472-8206.2007.00473.x","volume":"21","author":"SN Hilmer","year":"2007","unstructured":"Hilmer SN, McLachlan AJ, Le Couteur DG. Clinical pharmacology in the geriatric patient. Fund Clin Pharmacol. 2007;21(3):217\u201330.","journal-title":"Fund Clin Pharmacol"},{"key":"1369_CR56","unstructured":"Health Service Executive. Green Red antibiotic QI initiative for community prescribers. [Cited Date Accessed: 6 March, 2024]; Available from: https:\/\/www.hse.ie\/eng\/services\/list\/2\/gp\/antibiotic-prescribing\/antibicrobial-stewardship-audit-tools\/campaign-materials\/"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01369-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-024-01369-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01369-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T07:03:08Z","timestamp":1719212588000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-024-01369-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["1369"],"URL":"https:\/\/doi.org\/10.1007\/s40261-024-01369-9","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"15 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J.H., C.C. and K.B. were involved in the concept and design of the study. J.H. led on the analysis and interpretation of the results. J.H. prepared the first draft of the manuscript and C.C. and K.B. provided feedback. All authors read and approved the final manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Open Access funding provided by the IReL Consortium. This research was supported by funding from the Health Research Board Research Leader Award (grant number RL-15-1579) and the Irish Research Council Government of Ireland Postgraduate Scholarship Programme Award to J.H. (grant number GOIPG\/2021\/1213). C.C. is supported by funding from the Health Research Board (SDAP-2021-020). The funding bodies had no part in the study design, the identification, analysis, and collection of the data, or preparation of the manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All data generated or analysed during this study are included in this article (and its Supplementary Information files). The master DDI list (which includes full details on interaction effect, evidence and action) is available to other researchers upon reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"K.B. is in receipt of funding from IQVIA and Novartis for unrelated projects.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Ethical approval for this study was obtained from the RCSI Research Ethics Committee (REC 462b).","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants gave informed consent before taking part in the study.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}